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So one elephant with a trunk was odd, but all elephants having trunks looked like a plot.
G.K. Chesterton, The Ethics of Elfland.
A prominent vascular surgeon is approached by a representative of a large medical device company with a proposal to
implant a new self-sealing patch for closing open carotid endarterectomies. The patch is made of a new synthetic material
that establishes immediate hemostasis and inhibits restenosis in animal studies. It has just been approved for human use
by the Food and Drug Administration. The cost of the new patch is much higher than for established comparable
products, even when potential long-term benefits are considered, but using it would reduce the operative time required
for achieving hemostasis. The manufacturer’s representative tells you that the company will pay a selected group of
vascular surgeons $500 apiece each time they insert the patch on their patients and complete a one-page report. Surgeons
with the highest volume of cases utilizing the patch will be offered a paid clinical consultancy with the company. You’ve
used another company’s product for several years and found it entirely satisfactory, but have followed development of the
new patch with interest and considered trying it in your patients having carotid endarterectomies. What should you do?
A. Join the study. You probably would have used the new patch on your patients anyway.
B. If the early data warrant, implant the patch on a trial basis without enrolling in the project, and finally decide whether
to continue using it based on your clinical experience and additional published reports.
C. Call some of the other investigators who have already enrolled in the project and ask them about their experience.
D. Decline the invitation immediately. Refuse to ever speak to the representative again.
E. Estimate the ability of your patients to sustain the high cost of the new product and decide accordingly whether to use
it. ( J Vasc Surg 2006;43:192-5.)It may be that the recent felony convictions of some
high-profile corporate scoundrels will herald a new era of
ethical practice in our high-stakes market places. The last
several years have seen all sorts of traditional winners and
icons become suspect. For juiced athletes, high-rolling TV
preachers, and business over-friendly politicians, the lure of
money, and more money, now and as ever, turns trust into
a negotiable commodity and ethical boundaries into mov-
ing targets.
From The Center for Medical Ethics and Health Policy, Baylor College of
Medicine,aand the Department of Psychiatry, University of Missouri.b
Correspondence: James W. Jones, MD, PhD, MHA, Center for Medical
Ethics and Health Policy, Baylor College of Medicine, One Baylor Plaza,
Houston, TX 77030 (e-mail: jwjones@bcm.tmc.edu).
0741-5214/$32.00
Copyright © 2006 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.10.015
192Has medicine remained pure amid this seemingly per-
vasive culture of corruption and rapacious self-interest?
More and more, the effluvium arising from the halls of the
medical-industrial complex has taken on an insidiously
purulent quality. An assistant professor of orthopedic sur-
gery was just fined $10,000 for implanting expensive knee
prostheses without telling his patient that the devices were
made by a company that paid him a $175,000 annual
consulting fee.1 Maybe the choice of the company’s pros-
thesis was appropriate to the patient’s conditions, and
maybe the surgeon’s failure to report his paid consultancy
was an unintentional oversight, but his state ethics board
felt like the whole thing didn’t pass its smell test.
That case wasn’t the only source of the peculiar odor
that’s been in the air. Not long ago, the New York Times
reported that Guidant Corporation paid 80 cardiologists
$1,000 each to implant three of the company’s new leads in
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the $29,000 product worked.2 A Guidant executive, advo-
cating the physician payment program in an in-house
memo, wrote, “Let’s say that just 25% were incremental . . .
that yields more than $2 million in new sales with physi-
cians who are not necessarily Guidant-friendly. We paid
each physician who completed all surveys $1,000, so our
total cost was $80,000.” The company appears to have
made the honoraria to promote sales and not, as one of the
participating cardiologists said in justifying his role, “to get
feedback on how well the system worked.”2
Accepting consultancies, honoraria, or gifts from med-
ical equipment and pharmaceutical manufacturers creates
the potential for conflicts of interest regardless of the
arrangements or qualifying terminology.3 Financial conflicts
of interest create a competitive relationship between the phy-
sician’s fiduciary obligations to the patient and the physician’s
economic self-interest. Fiduciary obligations are founded in
professional integrity, the essential professional virtue that
obligates us to practice medicine and conduct research
consistent with standards of intellectual and moral excel-
lence. The patients who permit us to practice our invasive
procedures upon them when they are most vulnerable need
to believe that we always exercise professional integrity and
that our clinical judgments are always made on the basis of
our hard-won knowledge and experience. Giving primacy
to financial self-interest in one’s practice, or permitting
personal financial interests to influence clinical judgment
and decisions, clearly violates that trust, without which we
cannot function as a profession. For us, as with wayward
athletes, clergymen, politicians, or industrialists, money
coming in over the transom distorts professional integrity.
For us alone, it can imperil the lives and health of patients.
Few medical specialties are more dependent upon ad-
vanced technology than surgery. The collaboration of phy-
sician expertise and industrial capital is almost always critical
to development of the ever-more complex and imaginative
tools we use to broaden our ability to soothe and to heal.
Certainly, no one could sensibly advocate the development
of medical technology unguided by the expertise of prac-
ticing clinicians. The effectiveness as well as the integrity of
intellectual partnerships between doctors and medical
product manufacturers can only be assured, however, when
physicians disinterestedly observe scientific principles un-
contaminated by business principles and businessmen do
not permit their profit motives to impinge upon the scien-
tific process. Famed economic philosopher Adam Smith
called the process “enlightened self-interest,” recognizing
that everyone liked the idea of self-interest, but that it could
only be durably achieved, and achieve the societal benefit
which would ensure its durability, when people took the
trouble to become enlightened about all its implications.
The system of communication between physicians and
the manufacturers of products they use in their practices
certainly originated in the context of scientific collabora-
tion, and certainly, that legitimate and valuable kind of
partnership continues to this day. The medical product
industry funds an enormous amount of important basic andclinical science in academic research centers around the
western world. Somewhere along the way, though, the
medical manufacturers’ marketing departments shouldered
their way into the process and introduced the techniques of
advertising and salesmanship to what medical professionals
had been led to believe was a relationship built on their
scientific and clinical expertise. Though told otherwise, it
was no longer just the doctor’s expert opinions and re-
search programs that were sought, it was his influence as a
sales broker for expensive products he ordered at his pa-
tients’ expense. And the cost to the company of the doc-
tor’s confidence in the usefulness of the product was often
only a “consultancy” fee, or travel expenses to a “scientific
meeting,” or maybe even just dinner at the elegant restau-
rant where detail reps supervised an “educational presenta-
tion.” Acquaintances were warmed, good feelings gener-
ated, and obligations gently accumulated. If anyone saw
through the thin disguises, nobody had the poor taste to
mention it, and everyone went home comfortable. Waud
had the temerity to write that every kind of gift from the
medical industry to physicians was a bribe, an inducement
for doctors to buy instruments, contraptions, and medica-
tions that someone else finally gets billed for.4
Financial conflicts of interest aren’t rare in medicine.
They’re encouraged by the medical product industry’s mar-
keting divisions, and are epidemic. Topol recently esti-
mated that 10% of physicians had consulting relationships
with the investment industry,5 but the actual incidence of
some sort of potentially compromising entanglement be-
tween doctors, particularly academic physicians, and med-
ical product manufacturers appears to be much higher.
Ninety-six percent of respondents in a 2004 study had
received some kind of gift or other inducement from the
medical equipment or pharmaceutical industry.6 Most of
the physicians who accepted gifts from pharmaceutical
companies acknowledged that the company’s intent was to
influence their practice, but still believed that it was not
inappropriate for them to accept what was offered. They
nevertheless did not want their acceptances made public.7
Patients generally disapproved of physician gifts, such as
restaurant meals, that were unrelated to their medical prac-
tice (48.4%), but were less critical of free medical books.7
Most significantly, 70% of patients believed that physicians’
practices were influenced by gifts, and 64% thought that
gifts to physicians from medical companies added to the
cost of their medical care.
Innovation and technology, inseparable necessities of
the surgeon’s armamentarium, produce most of the major
advances in surgery. Most of the surgical device technology
originates in industry R&D sections, not merit review
grant-supported research in academic clinical and basic
science labs. Even when generated peripherally, the com-
mercial rights to medical devices are typically sold to indus-
tries that proceed to patent, test, and put them into pro-
duction. Industry is an essential component of medical
practice and physicians are an essential component of the
medical industry. But roses always have thorns. Industrial
money, disguised as research support, can easily be slipped
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York Times expose appears to have done. A paid medical
consultant necessarily becomes a company employee, and
companies not unexpectedly expect their employees’ loy-
alty.
Appointing lots of physicians as “investigators” to curry
favor on behalf of medical products and thus stimulate sales
is becoming painfully common, but because industry still
supports an enormous amount of legitimate science, phy-
sicians must learn to distinguish the two activities from one
another when industry comes calling.9 The absence of a
research protocol, generation of unpublishable data, inap-
propriately high compensation, lavish travel perks, inclu-
sion of inexperienced “investigators,” appointment of an
excessive contingent of “investigators,” and lack of over-
sight are tip-offs that the physician is probably being ap-
proached by a company’s marketing division rather than its
research arm, and that the plan is to ultimately to generate
loyalties and boost sales rather than develop reproducible
scientific data.
Spurred by a Congressional investigation, a flurry of
indignant articles condemning industry’s unethical market-
ing forays appeared in the early 1990s, but the indignation
cooled and the compromising practices have crept back to
where they were, with fewer complaints. A good deal of the
public outrage stemmed from an intuition that the medical
product industry should observe the same ethical principles
that the guide the medical profession. The industries that
manufacture our instruments, therapeutic devices, and nos-
trums have taken some pains to argue that they share and
abide by the principles of medical ethics, but they are most
pious in these protestations only when the bright lights are
on.
Guardianship of medical ethics is finally the responsi-
bility of physicians, and if we leave the job to others, we will
inevitably see medical ethics in ashes. The American Col-
lege of Surgery’s position on collaboration with industry
appears to be limited to the College’s own role in managing
money it receives frommedically related industries, without
much concern for the responsibilities of individual surgeons
in handling their potential conflicts of interest when big
business knocks on the office door. The College’s state-
ment suggests that an ethical line is crossed when patient
care is improperly influenced: “The primary objective of
professional interactions between surgeons or surgical or-
ganizations and industry should be the improvement of
patient care. It is the responsibility of surgeons to ensure
that this care is not inappropriately affected by collabora-
tion with industry.”8 The Royal College of Surgeons of
England is only a little more helpful. It suggests that, “If
you have financial or commercial interests in organizations
providing health care or in pharmaceutical or other bio-
medical companies, these must not affect the way you
prescribe for, treat or refer patients.”9 These torpid posi-
tions seem to be about as much as our professional leaders
have been willing to commit to on the subject of industry
contamination of the surgeon’s practice. The other major
international surgical organizations have been content tolie suspiciously mute in the matter; their annual meetings
are of course generously subsidized and their journals lav-
ishly supported by manufacturers’ advertising dollars.
The Royal College of Physicians’ position statement is
more direct on the subject of physicians’ financial relations
with industry. It advises that, “Doctors should avoid ac-
cepting any pecuniary or material inducement that might
compromise, or be regarded by others as likely to compro-
mise, the independent exercise of their professional judg-
ment and practice.”10 The Royal College of Physicians
suggests that physicians not place themselves in a compro-
mised position. All their meeker surgical colleagues seem
able to manage by contrast is a recommendation that we
accept what industry offers us and then somehow summon
the ethical fortitude to deny our gentle benefactors the
influence they’ve purchased when we make our patient care
decisions. One statement keeps the fox out of the hen-
house, the other throws open the henhouse doors but
expresses hope that the fox won’t eat anything while he’s in
there. In the history of the world, only the Manicheans are
known to have had such discriminative powers, and the
Manicheans have long been gone.
The American Medical Association provides good
guidance on the appropriate ethical terms for entering a
financial relationship with the medical product industry:
“Any financial compensation received from trial sponsors
must be commensurate with the efforts of the physician
performing the research. Financial compensation should be
at fair market value and the rate of compensation per
patient should not vary according to the volume of subjects
enrolled by the physician, and should meet other existing
legal requirements.”11
Physicians interested in behaving ethically should avoid
the kinds of rationalizations suggested in Option A.We can
probably all think of good reasons for bad actions, particu-
larly when easily reached rewards are dangled before us. Are
the reasons we plug in sufficiently compelling to risk vio-
lating the trust our patients have in us? Are they likely to
improve the quality of the care we provide? The answers to
these questions are unlikely to lure the thoughtful physician
into abandoning professional integrity, and the first of the
options offered here should be rejected.
Option C may appear at first to have some virtue. We
certainly consult experienced and trusted professional col-
leagues when we are about to do a new procedure for the
first time, or when we are considering recruiting to our own
staffs a surgeon with whom they have prior familiarity. But
it may be too late to get an objective opinion about the new
patch from a colleague who has already signed up for this
questionable “study”; his loyalty to the product has already
been bought and paid for. Cynical as such a view of a fellow
professional might seem, the chances of a frank or critical
assessment are probably slim, and it would be difficult to
distinguish a carefully considered and well-supported pos-
itive report from one that has been compromised by a
conflict of interest. Option C is ultimately not a reliable
choice.
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any sort of cooperative relationship with industry, over-
looks the importance of ethically sound partnerships be-
tween surgeons and the companies that make the tools of
our trade. If surgeons decline to provide expert guidance to
surgical instrument and supply manufacturers, who will?
How responsive to our needs can they be if we never tell
them what we need in the products they deliver to us?
A better approach than disdainful, out-of-hand rejec-
tion would be to hear what’s being proposed, remaining
alert to the red flags suggesting potential exploitation and
manipulation. If we have the scientific training and the
resources, of course we may properly consider participating
in a scientifically sound, protocol-based study that will yield
reproducible publishable data and make a genuine contri-
bution to the accumulated body of professional knowledge.
Expenses incurred by your program in conducting a well-
designed study should be covered by the sponsor, but
assurances of personal enrichment should raise your skep-
tical antennae. And before agreeing to do any company-
sponsored research study, you should establish in writing
your entitlement to publish your findings independent of
company control.
Certainly your patients will appreciate your sensitivity
to the costs they incur in seeking surgical care, but it is no
less odious for you to make clinical decisions solely on the
basis of cost than it is for managed care clerks do it.
Particularly when major illnesses requiring major surgery
are involved, your patients want you to provide them with
outstanding care before they want you to provide them
with inexpensive care. If you have legitimate reason to
believe that the expensive new patch is the best choice for
your patient’s individual clinical condition, you are ethically
obligated to use it. All your patient asks is that your decision
be made on the basis of clinical indications, not marketing
manipulations. Option E is not an ethically sound ap-
proach.
Option B reflects the methods that thoughtful and
ethical surgeons use in making virtually all their clinical
decisions, without regard to the soothing assurances of
manufacturers’ reps, lucrative consultancies, or four-coloradvertising brochures. It is the same process we use when
none of these seductions are in the picture. It relies upon
your training, your intellect, your clinical experience, your
independent study of the peer-reviewed literature, and your
individual assessment of your patient’s unique clinical char-
acteristics. The preservation of your judgment and integ-
rity, and the quality of your care, is assured if you avoid
unstable situations with a high risk for ethical compromise.
Not every proposal you’ll receive from every side is in-
tended to corrupt you, but only physicians, not foxes, are
bound to honor our exacting system of ethics, and those
ethical principles are clearly anathema to elements that
would turn us to their own purposes. We must guard our
own henhouses.
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